HEIDELBERG, Germany--Gene Bridges GmbH, the recombineering company, today announced that Chugai Pharmaceutical Co., Ltd. of Tokyo, Japan has completed the amendment to expand the commercial license agreement existing since 2005 for the use of the Red/ET recombination technology from Gene Bridges.
The Red/ET recombination technology, patented in Japan under the title "Novel DNA Cloning Method“, is a valued method for generating targeting vectors or modifying E. coli chromosomes.
“Red/ET is fast becoming the standard DNA engineering technology used in industry and academia worldwide,” commented Gary Stevens, CEO of Gene Bridges GmbH. “Having recently also licensed Red/ET to Daiichi Sankyo and Takeda we are delighted to be signing this amendment to another leading Japanese Pharmaceutical company, which found the existing license agreement worthwhile expanding.”
Red/ET is a revolutionary method for DNA engineering. Recombineering with Red/ET allows cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including very large ones such as BACs or the E.coli chromosome. Recombineering DNA using Red/ET has a number of advantages over conventional methods:
Independent of restriction sites
No size limits
No unwanted mutations
Rapid
Red/ET Recombineering is one simple and powerful tool to modify plasmids, BACs, and even E.coli chromosomes. Gene Bridges is represented in Japan by the distribution partner Funakoshi.
The Red/ET recombination technology, patented in Japan under the title "Novel DNA Cloning Method“, is a valued method for generating targeting vectors or modifying E. coli chromosomes.
“Red/ET is fast becoming the standard DNA engineering technology used in industry and academia worldwide,” commented Gary Stevens, CEO of Gene Bridges GmbH. “Having recently also licensed Red/ET to Daiichi Sankyo and Takeda we are delighted to be signing this amendment to another leading Japanese Pharmaceutical company, which found the existing license agreement worthwhile expanding.”
Red/ET is a revolutionary method for DNA engineering. Recombineering with Red/ET allows cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including very large ones such as BACs or the E.coli chromosome. Recombineering DNA using Red/ET has a number of advantages over conventional methods:
Independent of restriction sites
No size limits
No unwanted mutations
Rapid
Red/ET Recombineering is one simple and powerful tool to modify plasmids, BACs, and even E.coli chromosomes. Gene Bridges is represented in Japan by the distribution partner Funakoshi.
No comments:
Post a Comment